Sign up
Matches 51 - 100 out of 156 < 1 2 3 4 >


Match Document Document Title
7335639 IGF-1 composition and its use  
A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I...
7304029 Neuroprotective effect of growth hormone  
The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising...
7288516 Null IGF for the treatment of cancer  
New methods for the treatment of cancer are provided. Null IGF (IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer.
7276481 Method and composition for treatment of skeletal dysplasias  
The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been...
7268112 Use of insulin for the treatment of cartilaginous disorders  
The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the...
7262168 Compositions providing for increased IGF-I solubility  
Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs...
7238658 Crystallization of IGF-1  
Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising...
7232798 Neuroprotection and neuroegenisis by administering cyclic prolyl glycine  
The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurolo...
7226907 Cardiac muscle function and manipulation  
A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte...
7186686 Formulated composition  
A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl...
7173005 Insulin and IGF-1 receptor agonists and antagonists  
Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed....
7160857 Methods for increasing schwann cell survival  
Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.
7118752 Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I  
A method is described for using an a-type or b-type E domain of the human or trout IGF peptide for the inhibition of proliferation and invasiveness of a broad spectrum of malignant cells and for...
7105167 Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant  
IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder...
7087577 Method of promoting natural bypass  
An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The...
7074397 Method for enhancing proliferation or differentiation of a cell using ob protein  
Uses for WSX ligands in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for stimulating hematopoiesis (e.g., myelopoiesis, erythropoiesis and especially, lymphopoiesis)...
7071162 Combined use of cementum attachment protein and cyclosporin a for improved attachment of dental and orthopedic implants  
A method is described for inducing the formation of cementum and a periodontal ligament between a dental implant and bone by administering cementum attachment protein (CAP) together with a...
6974681 Cell culture performance with vanadate  
The invention provides methods and compositions for improved in vitro culture of cells that make use of vanadate. The methods enhance cell survival thereby recovery of the polypeptide of interest...
6946443 Biomaterial based on an insolubilized dextran derivative and a growth factor  
The invention concerns a biologically active material essentially comprising at least an insolubilized dextran derivative of general formula DMCaBbSUcSd and at least a growth factor having an...
6927204 Treatment of inner ear hair cells  
Compositions, methods, and devices are provided for inducing or enhancing the growth, proliferation, regeneration of inner ear tissue, particularly inner ear hair cells. In addition, provided are...
6881398 Therapeutic dry powder preparation  
A therapeutic dry powder preparation and a method of administering such a preparation are disclosed for effectively de-aggregating and dispersing into air a dose of medication powder in an...
6852687 Method for inhibiting apoptosis  
The present invention relates to a method for treating a subject having a condition or disease involving apoptosis, which comprises administering an effective amount of albumin to the subject. The...
6723344 Controlled release of non heparin-binding growth factors from heparin-containing matrices  
Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or...
6677500 Ungulates expressing exogenous IGF-I in their milk  
The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also...
6645945 Method of treating diseased, injured or abnormal cartilage with hyaluronic acid and growth factors  
A composition is provided for treating diseased, injured or diseased cartilage comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to...
6610302 Anti-tumor activity of Ea-2 and Ea-4-peptide of pro-IGF-I  
Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.
6565842 Crosslinkable polypeptide compositions  
In accordance with the present invention, there are provided rapidly crosslinkable polypeptides which are obtained upon introduction of unsaturated group(s) into the polypeptide via linkage to...
6528479 Dominant negative mutants of IRS-1 and uses thereof  
Dominant negative mutants of mammalian IRS-1 proteins and therapeutic compositions containing such mutants. Also featured are methods of using the dominant negative mutants to inhibit tyrosyl...
6506727 Nerve regeneration  
It has been found that the growth factor PDGF, when used in combination with another growth factor such as IGF-I, acts synergistically with the other factor to promote neuronal regeneration.
6468543 Methods for promoting growth of bone using ZVEGF4  
Methods for promoting growth of bone, ligament, or cartilage in a mammal are disclosed. The methods comprise administering to said mammal a composition comprising a pharmacologically effective...
6461613 Methods and compositions for the selective regulation of chorionic prostanoids  
Methods for inhibiting the production of specific vasoconstrictive prostanoids, such as thromboxane and prostaglandin F2α, through the addition of insulin like growth factor, particularly IGF-I or ...
6436897 Pharmaceutical formulations for IGF/IGFBP  
New pharmaceutical formulations for IGF/IGFBP complex are disclosed. IGF/IGFBP complex, preferably rhIGF-I/IGFBP-3 complex is formulated with bulking agents and optionally buffer salts, but without...
6326154 Ligand-mediated immunofunctional hormone binding protein assay method  
A ligand=mediated immunofunctional assay (LIFA) method for detecting the presence and the concentration of polypeptide hormone binding proteins which comprises capturing the binding protein with a...
6310040 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs  
Disclosed is a method for promoting retinal neuronal survival in a mammal, wherein the neuronal cells are at risk of dying. The method comprises administering to the mammal an effective dose of at...
6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same  
The invention provides a drug-oligomer conjugate having the following general formula: ##STR1##wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently selected...
6309381 Use of human growth hormone to treat acute myocardial infarction  
A method of treating an acute myocardial infarction (AMI) using human growth hormone to prevent most of the complications and the destructive process of cells and collagen framework which are...
6306432 High and low load formulations of IGF-I in multivesicular liposomes  
Disclosed are multivesicular liposomes (MVLs) containing IGF-I with substantially full bioavailability, wherein the loading of the IGF-I into the liposomes is modulated by adjusting the osmolarity...
6284282 Method of spray freeze drying proteins for pharmaceutical administration  
The present invention relates to the spray freeze dry preparation of dry powder formulations of therapeutic proteins suitable for administration via pulmonary delivery.
6211142 Compositions comprising gas6 polypeptides and articles of manufacture comprising the same  
An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides compositions...
6207640 Treatment of partial growth hormone insensitivity syndrome  
Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering an...
6183784 Method of ameliorating alimentary tract damage due to chemotherapy or radiation  
A milk product extract composiiton including a plurality of cell growth stimulating factors, extracted from milk product, in concentrated form; said factors having basic to approximately neutral...
6180606 Compositions with enhanced osteogenic potential, methods for making the same and uses thereof  
Osteogenic compositions, and methods for preparing same, which compositions comprise a porous or semi-porous matrix, an osteogenic factor and an agent such as growth factors, nutrient factors,...
6180603 Method for administering neurologic agents to the brain  
Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.
6153582 Defined serumfree medical solution for ophthalmology  
A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements, and a growth factor(s) which maintains and enhances the preservation of...
6136785 Protection from loss of sensory hair cells in the inner ear by administration of insulin-like growth factor and platelet derived growth factor  
The invention relates to a method for protecting sensory hair cells of the inner ear from damage caused by ototoxic drugs, in particular, aminoglycoside antibiotics, by administering to a...
6124264 Heterocyclic compounds  
This invention is directed to compounds of formula (I) and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone...
6087090 Methods for predicting drug response  
Methods are provided for formulating models for predicting whether subjects will respond to a particular drug or treatment regimen. Biochemical profiles are obtained (by measuring a variety or...
6043251 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis  
PCT No. PCT/FR96/01674 Sec. 371 Date Sep. 14, 1998 Sec. 102(e) Date Sep. 14, 1998 PCT Filed Oct. 25, 1996 PCT Pub. No. WO97/15304 PCT Pub. Date May 1, 1997The present invention relates to the use...
6025368 Method for treating the symptoms of chronic stress-related disorders using IGF  
Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated...
6024734 Treatment methods using homeopathic preparations of growth factors  
The present invention comprises homeopathic dilutions of growth factors and methods for their use. Disorders which may be effectively treated with the compositions of the present invention include...
Matches 51 - 100 out of 156 < 1 2 3 4 >